echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > China Chemical > Fibrant announces that the production of cyclohexanone and caprolactam has encountered force majeure

    Fibrant announces that the production of cyclohexanone and caprolactam has encountered force majeure

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 22, 2021, Fibrant announced force majeure because its main raw material supplier had to cut production due to floods in Northwestern Europe
    .


    The reduction in the supply of raw materials caused Fibrant to also be forced to reduce production


    The flood affected the infrastructure for the transportation of naphtha, a key raw material
    .


    It is expected that Fibrant's operating rate will take several weeks to return to normal levels


    The products included in the force majeure statement are:

    • Cyclohexanone

    • Caprolactam

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.